Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients
| Autor: | Anne-Ségolène Cottereau, Michel Meignan, Lars Jelstrup Petersen, Hervé Tilly, Martin Hutchings, Stéphanie Becker, John O. Prior, Tarec Christoffer El-Galaly, Christophe Bonnet, Florence Broussais, Olivier Casasnovas |
|---|---|
| Přispěvatelé: | Service de médecine nucléaire [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Aarhus University Hospital, Service de médecine nucléaire [Rouen], CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), The Lymphoma Academic Research Organisation [Lyon] (LYSARC), Centre Hospitalier Universitaire de Liège (CHU-Liège), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hématologie, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon) |
| Předmět: |
Adult
Male Interim PET PTCLs Adolescent Lymphoma PET/CT PET-CT lymphoma [SDV.CAN]Life Sciences [q-bio]/Cancer Oncology: Lymphoma 030218 nuclear medicine & medical imaging Young Adult 03 medical and health sciences 0302 clinical medicine Positron Emission Tomography Computed Tomography Journal Article Humans Medicine interim PET Radiology Nuclear Medicine and imaging Young adult Aged Retrospective Studies Aged 80 and over business.industry Lymphoma T-Cell Peripheral Metabolic tumor volume Retrospective cohort study Middle Aged Prognosis medicine.disease Predictive value Interim pet Peripheral T-cell lymphoma Tumor Burden 3. Good health Treatment Outcome 030220 oncology & carcinogenesis Female business Nuclear medicine metabolic tumor volume |
| Zdroj: | ResearcherID Journal of Nuclear Medicine Journal of Nuclear Medicine, Society of Nuclear Medicine, 2018, 59 (4), pp.589-595. ⟨10.2967/jnumed.117.193946⟩ Cottereau, A-S, El-Galaly, T C, Becker, S, Broussais, F, Peterson, L J, Bonnet, C, Prior, J O, Tilly, H, Hutchings, M, Casasnovas, O & Meignan, M A 2018, ' Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients ', Journal of Nuclear Medicine, vol. 59, no. 4, pp. 589-595 . https://doi.org/10.2967/jnumed.117.193946 |
| ISSN: | 0161-5505 |
| DOI: | 10.2967/jnumed.117.193946⟩ |
| Popis: | Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas with poor outcomes on current therapy. We investigated whether response assessed with PET/CT combined with baseline total metabolic tumor volume (TMTV) could detect early relapse or refractory disease. Methods: From 7 European centers, 140 patients with nodal PTCL who underwent baseline PET/CT were selected. Forty-three had interim PET (iPET) performed after 2 cycles (iPET2), 95 had iPET performed after 3 or 4 cycles (iPET3/4), and 96 had end-of-treatment PET (eotPET). Baseline TMTV was computed with a 41% SUV max threshold, and PET response was reported using the Deauville 5-point scale. Results: With a median of 43 mo of follow-up, the 2-y progression-free survival (PFS) and overall survival (OS) were 51% and 67%, respectively. iPET2-positive patients (Deauville score $ 4) had a significantly worse outcome than iPET2-negative patients (P, 0.0001, hazard ratio of 6.8 for PFS; P, 0.0001, hazard ratio of 6.6 for OS). The value of iPET3/4 was also confirmed for PFS (P, 0.0001) and OS (P, 0.0001). The 2-y PFS and OS for iPET3/4-positive (n 5 28) and iPET3/4-negative (n 5 67) patients were 16% and 32% versus 75% and 85%, respectively. The eotPET results also reflected patient outcome. A model combining TMTV and iPET3/4 stratified the population into distinct risk groups (TMTV # 230 cm 3 and iPET3/4-negative [2-y PFS/OS, 79%/85%]; TMTV . 230 cm 3 and iPET3/4-negative [59%/84%]; TMTV # 230 cm 3 and iPET3/4-positive [42%/50%]; TMTV . 230 cm 3 and iPET3/4-positive [0%/18%]). Conclusion: iPET response is predictive of outcome and allows early detection of high-risk PTCL patients. Combining iPET with TMTV improves risk stratification in individual patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|